WO1997006804A1 - 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis c - Google Patents
1,3-oxathiolane nucleoside analogues in the treatment of hepatitis c Download PDFInfo
- Publication number
- WO1997006804A1 WO1997006804A1 PCT/EP1996/003601 EP9603601W WO9706804A1 WO 1997006804 A1 WO1997006804 A1 WO 1997006804A1 EP 9603601 W EP9603601 W EP 9603601W WO 9706804 A1 WO9706804 A1 WO 9706804A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- hepatitis
- treatment
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU69247/96A AU6924796A (en) | 1995-08-19 | 1996-08-16 | 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis c |
JP9508948A JPH11512083A (en) | 1995-08-19 | 1996-08-16 | 1,3-oxathiolane nucleoside analogs in the treatment of hepatitis C |
EP96930043A EP0844878A1 (en) | 1995-08-19 | 1996-08-16 | 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis c |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9517022.1A GB9517022D0 (en) | 1995-08-19 | 1995-08-19 | Medicaments |
GB9517022.1 | 1995-08-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997006804A1 true WO1997006804A1 (en) | 1997-02-27 |
Family
ID=10779487
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1996/003601 WO1997006804A1 (en) | 1995-08-19 | 1996-08-16 | 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis c |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0844878A1 (en) |
JP (1) | JPH11512083A (en) |
AU (1) | AU6924796A (en) |
GB (1) | GB9517022D0 (en) |
WO (1) | WO1997006804A1 (en) |
ZA (1) | ZA966969B (en) |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997033565A1 (en) * | 1996-03-13 | 1997-09-18 | Glaxo Group Limited | Nucleoside compositions containing paracellular absorption enhancers |
WO2000064427A2 (en) * | 1999-04-22 | 2000-11-02 | Glaxo Wellcome Kabushiki Kaisha | Lamivudine containing pharmaceutical formulation |
US6143715A (en) * | 1997-08-11 | 2000-11-07 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor peptide analogues |
WO2001007027A2 (en) * | 1999-07-22 | 2001-02-01 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives for the treatment of viral diseases |
US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
US6767991B1 (en) | 1997-08-11 | 2004-07-27 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor peptides |
US6869964B2 (en) | 2002-05-20 | 2005-03-22 | Bristol-Myers Squibb Company | Heterocyclicsulfonamide hepatitis C virus inhibitors |
US6878722B2 (en) | 2002-05-20 | 2005-04-12 | Bristol-Myers Squibb Company | Substituted cycloalkyl P1′ hepatitis C virus inhibitors |
WO2005037214A2 (en) | 2003-10-14 | 2005-04-28 | Intermune, Inc. | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication |
US6995174B2 (en) | 2002-05-20 | 2006-02-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7012066B2 (en) | 2000-07-21 | 2006-03-14 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
US7041698B2 (en) | 2002-05-20 | 2006-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7169760B2 (en) | 2000-07-21 | 2007-01-30 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
WO2007044893A2 (en) | 2005-10-11 | 2007-04-19 | Intermune, Inc. | Compounds and methods for inhibiting hepatitis c viral replication |
US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
US7309708B2 (en) | 2003-11-20 | 2007-12-18 | Birstol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP1968595A2 (en) * | 2005-12-02 | 2008-09-17 | Yale University | Methods of treating cancer and other conditions or disease states using l-cytosine nucleoside analogs |
EP2028186A2 (en) | 1998-08-10 | 2009-02-25 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor tri-peptides |
US7511157B2 (en) | 2004-07-20 | 2009-03-31 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor dipeptide analogs |
US7585845B2 (en) | 2003-05-21 | 2009-09-08 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor compounds |
EP2103623A2 (en) | 2005-07-25 | 2009-09-23 | Intermune, Inc. | Novel macrocyclic inhibitors of Hepatitis C virus replication |
US7642235B2 (en) | 2003-09-22 | 2010-01-05 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
US7696242B2 (en) | 2004-07-20 | 2010-04-13 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor peptide analogs |
US7749961B2 (en) | 2004-01-21 | 2010-07-06 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
EP2392580A1 (en) * | 1998-02-25 | 2011-12-07 | Emory University | 2'-fluoronucleosides |
US8178491B2 (en) | 2007-06-29 | 2012-05-15 | Gilead Sciences, Inc. | Antiviral compounds |
US8513186B2 (en) | 2007-06-29 | 2013-08-20 | Gilead Sciences, Inc. | Antiviral compounds |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101201552B1 (en) * | 2000-10-18 | 2012-11-15 | 파마셋 인코포레이티드 | Modified nucleosides for treatment of viral infections and abnormal cellular proliferation |
US20050058044A1 (en) * | 2003-09-12 | 2005-03-17 | Koegler John M. | Optical disk modified for speed and orientation tracking |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992011852A1 (en) * | 1991-01-03 | 1992-07-23 | Biochem Pharma Inc. | Use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis b |
-
1995
- 1995-08-19 GB GBGB9517022.1A patent/GB9517022D0/en active Pending
-
1996
- 1996-08-16 JP JP9508948A patent/JPH11512083A/en active Pending
- 1996-08-16 ZA ZA966969A patent/ZA966969B/en unknown
- 1996-08-16 AU AU69247/96A patent/AU6924796A/en not_active Abandoned
- 1996-08-16 EP EP96930043A patent/EP0844878A1/en not_active Withdrawn
- 1996-08-16 WO PCT/EP1996/003601 patent/WO1997006804A1/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992011852A1 (en) * | 1991-01-03 | 1992-07-23 | Biochem Pharma Inc. | Use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis b |
Non-Patent Citations (3)
Title |
---|
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1996, SINCLAIR ET AL.: "benefits and safety of lamivudine (3TC) therapy in HIV positive patients with chronic hepatitis B or C", XP002019880 * |
DUSHEIKO: "management of chronic hepatitis b and c", SOUTH AFRICAN MED J, vol. 84, no. 8II, 1994, pages 563 - 570, XP002019764 * |
SINCLAIR ET AL., ELEVENTH INTERNATIONAL CONFERENCE ON AIDS,VANCOUVER,BRITISH COLUMBIA, CANDA, JULY 7-12 1996, 1996, pages 287 * |
Cited By (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997033565A1 (en) * | 1996-03-13 | 1997-09-18 | Glaxo Group Limited | Nucleoside compositions containing paracellular absorption enhancers |
US6767991B1 (en) | 1997-08-11 | 2004-07-27 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor peptides |
US6143715A (en) * | 1997-08-11 | 2000-11-07 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor peptide analogues |
EP2392580A1 (en) * | 1998-02-25 | 2011-12-07 | Emory University | 2'-fluoronucleosides |
EP2028186A2 (en) | 1998-08-10 | 2009-02-25 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor tri-peptides |
BG65738B1 (en) * | 1998-08-10 | 2009-09-30 | Boehringer Ingelheim (Canada) Ltd. | Tripeptide inhibitors of hepatitis c |
US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
WO2000064427A2 (en) * | 1999-04-22 | 2000-11-02 | Glaxo Wellcome Kabushiki Kaisha | Lamivudine containing pharmaceutical formulation |
WO2000064427A3 (en) * | 1999-04-22 | 2001-12-06 | Glaxo Wellcome Kabushiki Kaish | Lamivudine containing pharmaceutical formulation |
WO2001007027A3 (en) * | 1999-07-22 | 2001-08-09 | Vertex Pharma | Pyrimidine derivatives for the treatment of viral diseases |
WO2001007027A2 (en) * | 1999-07-22 | 2001-02-01 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives for the treatment of viral diseases |
US7169760B2 (en) | 2000-07-21 | 2007-01-30 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
US7595299B2 (en) | 2000-07-21 | 2009-09-29 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
US7012066B2 (en) | 2000-07-21 | 2006-03-14 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
USRE43298E1 (en) | 2000-07-21 | 2012-04-03 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
US6995174B2 (en) | 2002-05-20 | 2006-02-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7041698B2 (en) | 2002-05-20 | 2006-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US6869964B2 (en) | 2002-05-20 | 2005-03-22 | Bristol-Myers Squibb Company | Heterocyclicsulfonamide hepatitis C virus inhibitors |
US6878722B2 (en) | 2002-05-20 | 2005-04-12 | Bristol-Myers Squibb Company | Substituted cycloalkyl P1′ hepatitis C virus inhibitors |
US7585845B2 (en) | 2003-05-21 | 2009-09-08 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor compounds |
US7939667B2 (en) | 2003-05-21 | 2011-05-10 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor compounds |
US8067438B2 (en) | 2003-05-21 | 2011-11-29 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor compounds |
US7642235B2 (en) | 2003-09-22 | 2010-01-05 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
EP2407470A2 (en) | 2003-10-14 | 2012-01-18 | F. Hoffmann-La Roche Ltd. | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication |
WO2005037214A2 (en) | 2003-10-14 | 2005-04-28 | Intermune, Inc. | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication |
US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7309708B2 (en) | 2003-11-20 | 2007-12-18 | Birstol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7749961B2 (en) | 2004-01-21 | 2010-07-06 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
US7511157B2 (en) | 2004-07-20 | 2009-03-31 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor dipeptide analogs |
US7767818B2 (en) | 2004-07-20 | 2010-08-03 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor dipeptide analogs |
US7696242B2 (en) | 2004-07-20 | 2010-04-13 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor peptide analogs |
EP2103623A2 (en) | 2005-07-25 | 2009-09-23 | Intermune, Inc. | Novel macrocyclic inhibitors of Hepatitis C virus replication |
EP2305696A2 (en) | 2005-07-25 | 2011-04-06 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
EP2305697A2 (en) | 2005-07-25 | 2011-04-06 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
EP2305698A2 (en) | 2005-07-25 | 2011-04-06 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
EP2305695A2 (en) | 2005-07-25 | 2011-04-06 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
WO2007044893A2 (en) | 2005-10-11 | 2007-04-19 | Intermune, Inc. | Compounds and methods for inhibiting hepatitis c viral replication |
EP1968595A2 (en) * | 2005-12-02 | 2008-09-17 | Yale University | Methods of treating cancer and other conditions or disease states using l-cytosine nucleoside analogs |
EP1968595A4 (en) * | 2005-12-02 | 2014-05-21 | Univ Yale | Methods of treating cancer and other conditions or disease states using l-cytosine nucleoside analogs |
US8178491B2 (en) | 2007-06-29 | 2012-05-15 | Gilead Sciences, Inc. | Antiviral compounds |
US8513186B2 (en) | 2007-06-29 | 2013-08-20 | Gilead Sciences, Inc. | Antiviral compounds |
US8809266B2 (en) | 2007-06-29 | 2014-08-19 | Gilead Sciences, Inc. | Antiviral compounds |
US8809267B2 (en) | 2007-06-29 | 2014-08-19 | Gilead Sciences, Inc. | Antiviral compounds |
Also Published As
Publication number | Publication date |
---|---|
AU6924796A (en) | 1997-03-12 |
EP0844878A1 (en) | 1998-06-03 |
GB9517022D0 (en) | 1995-10-25 |
ZA966969B (en) | 1997-03-24 |
JPH11512083A (en) | 1999-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997006804A1 (en) | 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis c | |
EP0565549B1 (en) | Use of 1,3-oxathiolane nucleoside analogues in the manufacture of a medicament for treatment of hepatitis b | |
JP2818299B2 (en) | Use of dideoxynucleoside analogs in the treatment of viral infections | |
JP2008255121A (en) | Nucleoside with anti-hepatitis b virus activity | |
KR20180058828A (en) | Combination therapy of HBV capsid assembly inhibitor and interferon | |
JPH05202045A (en) | 1,3-oxathiolane useful for treating hepatitis | |
WO2010031832A2 (en) | Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative | |
JP2002528508A (en) | Combination therapy for the treatment of hepatitis B | |
EP2890378A2 (en) | Combination of a macrocyclic protease inhibitor of hcv, a non-nucleoside hcv inhibitor and ritonavir | |
CA2213621A1 (en) | Antiviral combinations of bch-189 and ritonavir | |
CA2140238C (en) | Antiviral combinations | |
KR20010075202A (en) | Antiviral Combinations Comprising Lamivudine and Abacavir | |
GB2400552A (en) | Pharmaceutical combinations for treating viral infections | |
AU4568893A (en) | Antiviral combinations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1996930043 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1997 508948 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1996930043 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996930043 Country of ref document: EP |